Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

Abstract

BACKGROUND No study has examined dopamine D₂/₃ receptor (D₂/₃R) availability in antipsychotic-free older patients with schizophrenia. METHODS We included patients with schizophrenia 50 years or older who were antipsychotic-free for at least 3 months. We compared non-displaceable binding potential (BPND) of [(11)C]-raclopride in the caudate, putamen, ventral striatum, and globus pallidus between patients and age- and sex-matched healthy controls. RESULTS Ten patients participated (antipsychotic-naive=4). No differences in BPND were found between patients and controls in any ROIs (F(1, 72)=.42, p=.52). CONCLUSION The preliminary results suggest no differences in D₂/₃R availability between antipsychotic-free older patients with schizophrenia and controls.

DOI: 10.1016/j.schres.2015.02.020

Cite this paper

@article{Nakajima2015DopamineDR, title={Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.}, author={Shinichiro Nakajima and Fernando Caravaggio and David C. Mamo and Benoit H. Mulsant and Jun Ku Chung and Eric Plitman and Yusuke Iwata and Philip Gerretsen and Hiroyuki Uchida and Takefumi Suzuki and Wanna Mar and Alan A. Wilson and Sylvain Houle and Ariel Graff-Guerrero}, journal={Schizophrenia research}, year={2015}, volume={164 1-3}, pages={263-7} }